N-terminal proBNP: a novel biomarker for the diagnosis, risk stratification and management of congestive heart failure.

Published

Journal Article (Review)

Congestive heart failure is a leading cause of morbidity and mortality throughout the world and is now the leading cause of hospitalizations in adults over 65 years of age with an estimated annual expenditure in excess of USD 20 billion. In addition, it is the only cardiovascular disorder that continues to increase in both incidence and prevalence, and as the population continues to age, it is expected that the prevalence of this disease will continue to rise. Ironically, the armamentarium of medications that decrease mortality due to congestive heart failure also continues to grow; however, the relative number of eligible patients with congestive heart failure (or at risk for congestive heart failure) that receive these important therapies remains low. Thus, better tools to aid the early diagnosis and management of this disease are needed. Testing for natriuretic peptide markers, such as B-type natriuretic peptide or its amino-terminal fragment, has emerged as an important tool to assist in the optimal diagnosis and risk stratification of patients with congestive heart failure and may also play a valuable role in guiding therapy.

Full Text

Duke Authors

Cited Authors

  • O'Donoghue, M; Januzzi, JL

Published Date

  • May 2005

Published In

Volume / Issue

  • 3 / 3

Start / End Page

  • 487 - 496

PubMed ID

  • 15889976

Pubmed Central ID

  • 15889976

Electronic International Standard Serial Number (EISSN)

  • 1744-8344

Digital Object Identifier (DOI)

  • 10.1586/14779072.3.3.487

Language

  • eng

Conference Location

  • England